Overview

A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies

Status:
Active, not recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
Open Label Phase 1/2 Trial of Tisotumab Vedotin in Japanese Subjects with Advanced Solid Malignancies
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Genmab
Collaborators:
Seagen Inc.
Seattle Genetics, Inc.
Treatments:
Tisotumab vedotin